Niamh E Buckley (N E Buckley, Niamh Buckley)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 14

Top Topics

Early Breast Cancer

Signaling Pathway

Immune Response

Top Venues

Journal of oncology

NPJ breast cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Rachel Bingham, Helen McCarthy, Niamh E Buckley
Exploring Retrograde Trafficking: Mechanisms and Consequences in Cancer and Disease. Traffic (Copenhagen, Denmark) 25 (2) (2024)
Kimberley Glass, Cory Fines, Paula Coulter, Lynn Jena, Helen O McCarthy, Niamh E Buckley
Development and Characterization of a Peptide-Bisphosphonate Nanoparticle for the Treatment of Breast Cancer. Molecular pharmaceutics (2024)
Alexa Little, Mark Tangney, Michael M Tunney, Niamh E Buckley
Fusobacterium nucleatum: a novel immune modulator in breast cancer? Expert reviews in molecular medicine (2023)
Sean P Kennedy, Oliver Treacy, Emma H Allott, Alexander J Eustace, Niamh Lynam-Lennon, Niamh E Buckley, Tracy Robson
Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference. Cancers 14 (24) (2022)
Sean P Kennedy, Oliver Treacy, Emma H Allott, Alexander J Eustace, Niamh Lynam-Lennon, Niamh E Buckley, Tracy Robson
Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference. Cancers 14 (24) (2022)
Eileen E Parkes, Matthew P Humphries, Elaine Gilmore, Fatima Abdullahi Sidi, Victoria Bingham, Su M Phyu, Stephanie Craig, Catherine Graham, Joseph Miller, Daryl Griffin, Manuel Salto-Tellez, Stephen F Madden, Richard D Kennedy, Samuel F Bakhoum, Stephen McQuaid, Niamh E Buckley
The clinical and molecular significance associated with STING signaling in breast cancer. NPJ breast cancer 7 (1) (2021)
Eileen E Parkes, Kienan I Savage, Tong Lioe, Clinton Boyd, Sophia Halliday, Steven M Walker, Keith Lowry, Laura Knight, Niamh E Buckley, Andrena Grogan, Gemma E Logan, Alison Clayton, Jane Hurwitz, Stephen J Kirk, Jiamei Xu, Fatima Abdullahi Sidi, Matthew P Humphries, Victoria Bingham, null null, Jaqueline A James, Colin R James, D Paul Harkin, Richard D Kennedy, Stuart A McIntosh
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. British journal of cancer (2021)
Catherine Knowlson, Paula Haddock, Victoria Bingham, Stephen McQuaid, Paul B Mullan, Niamh E Buckley
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer. Therapeutic advances in medical oncology 12 (2020)
Ahmed Elkashif, Victoria Bingham, Paula Haddock, Matthew Phillip Humphries, Stephen McQuaid, Paul B Mullan, Helen O McCarthy, Niamh E Buckley
Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer. Journal of oncology 2020 (2020)
Orla T Cox, Shelley J Edmunds, Katja Simon-Keller, Bo Li, Bruce Moran, Niamh E Buckley, Milan Bustamante-Garrido, Nollaig Healy, Ciara H O'Flanagan, William M Gallagher, Richard D Kennedy, René Bernards, Carlos Caldas, Suet-Feung Chin, Alexander Marx, Rosemary O'Connor
PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer. Cancer research 79 (10) (2019)
Richard D A Wilkinson, Roberta E Burden, Sara H McDowell, Darragh G McArt, Stephen McQuaid, Victoria Bingham, Rich Williams, Órla T Cox, Rosemary O'Connor, Nuala McCabe, Richard D Kennedy, Niamh E Buckley, Christopher J Scott
A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer. Journal of oncology 2019 (2019)
Paul B Mullan, Victoria Bingham, Paula Haddock, Gareth W Irwin, Elaine Kay, Stephen McQuaid, Niamh E Buckley
NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer. BMC cancer 19 (1) (2019)
Nyree T Crawford, A J McIntyre, A McCormick, Z C D'Costa, Niamh E Buckley, P B Mullan
TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells. Oncogene 38 (31) (2019)
Matthew Phillip Humphries, Seán O Hynes, Victoria Bingham, Delphine Cougot, Jacqueline A James, Farah Patel-Socha, Eileen E Parkes, Jaine K Blayney, Michael A O'Rorke, Gareth W Irwin, Darragh G McArt, Richard D Kennedy, Paul B Mullan, Stephen McQuaid, Manuel Salto Tellez, Niamh E Buckley
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of oncology 2018 (2018)